Compare PRTS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | NXTC |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 44.6M |
| IPO Year | 2006 | 2019 |
| Metric | PRTS | NXTC |
|---|---|---|
| Price | $0.79 | $12.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $0.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 775.3K | 24.1K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.23 |
| 52 Week High | $1.36 | $15.74 |
| Indicator | PRTS | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 46.44 |
| Support Level | $0.78 | $10.73 |
| Resistance Level | $0.92 | $13.47 |
| Average True Range (ATR) | 0.06 | 1.10 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 55.21 | 42.72 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.